IBB holdings - what the fund actually owns
iShares Biotechnology ETF reports 234 stock positions to the SEC, 100% of its assets. The ten largest are 44.8% of the fund, as of Jun 30, 2026.
Each week Ploutos reads the latest N-PORT filing of the largest US equity ETFs. This page is one fund's filing: its reported positions with their weights, where that weight sits by sector, what entered and left since the previous filing, and which other funds hold the most of the same stocks.
Reported positions
234
cover 100% of the fund
Weight of the top 10 holdings
44.8%
of the fund in ten names
Largest position
VRTX
8.08% · Vertex Pharmaceuticals, Inc.
Filing date
Jun 30, 2026
holdings as reported to the SEC
Where the weight sits, by sector
Healthcare
98.0%
Basic Materials
0.6%
Technology
0.5%
Unknown
0.8%
Sectors come from each company's industry code in its SEC record, so they are coarse. 0.8% of the reported weight could not be placed and is shown as unknown.
Full holdings list, heaviest first
| # | Stock | Weight | Cumulative |
|---|---|---|---|
| 1 | VRTXVertex Pharmaceuticals, Inc. | 8.08% | 8.1% |
| 2 | AMGNAmgen, Inc. | 7.83% | 15.9% |
| 3 | GILDGilead Sciences, Inc. | 6.84% | 22.8% |
| 4 | REGNRegeneron Pharmaceuticals, Inc. | 4.91% | 27.7% |
| 5 | ARGXArgenx SE | 3.76% | 31.4% |
| 6 | ALNYAlnylam Pharmaceuticals, Inc. | 3.12% | 34.5% |
| 7 | NTRANatera, Inc. | 2.89% | 37.4% |
| 8 | RVMDRevolution Medicines, Inc. | 2.78% | 40.2% |
| 9 | BIIBBiogen, Inc. | 2.47% | 42.7% |
| 10 | ILMNIllumina, Inc. | 2.07% | 44.8% |
| 11 | MRNAModerna, Inc. | 1.98% | 46.7% |
| 12 | INSMInsmed, Inc. | 1.78% | 48.5% |
| 13 | ONCBeOne Medicines Ltd. | 1.77% | 50.3% |
| 14 | INCYIncyte Corp. | 1.75% | 52.0% |
| 15 | UTHRUnited Therapeutics Corp. | 1.73% | 53.8% |
| 16 | ROIVRoivant Sciences Ltd. | 1.43% | 55.2% |
| 17 | NBIXNeurocrine Biosciences, Inc. | 1.30% | 56.5% |
| 18 | ASNDAscendis Pharma A/S | 1.29% | 57.8% |
| 19 | GMABGenmab A/S | 1.12% | 58.9% |
| 20 | EXELExelixis, Inc. | 1.03% | 59.9% |
| 21 | IONSIonis Pharmaceuticals, Inc. | 1.00% | 60.9% |
| 22 | BBIOBridgebio Pharma, Inc. | 0.98% | 61.9% |
| 23 | MEDPMedpace Holdings, Inc. | 0.95% | 62.9% |
| 24 | MDGLMadrigal Pharmaceuticals, Inc. | 0.91% | 63.8% |
| 25 | TECHBio-Techne Corp. | 0.86% | 64.6% |
| 26 | BMRNBioMarin Pharmaceutical, Inc. | 0.85% | 65.5% |
| 27 | ARWRArrowhead Pharmaceuticals, Inc. | 0.84% | 66.3% |
| 28 | CRLCharles River Laboratories International, Inc. | 0.84% | 67.2% |
| 29 | AXSMAxsome Therapeutics, Inc. | 0.82% | 68.0% |
| 30 | CYTKCytokinetics, Inc. | 0.79% | 68.8% |
| 31 | KRYSKrystal Biotech, Inc. | 0.75% | 69.5% |
| 32 | HALOHalozyme Therapeutics, Inc. | 0.72% | 70.2% |
| 33 | PRAXPraxis Precision Medicines, Inc. | 0.68% | 70.9% |
| 34 | ABVXAbivax SA | 0.67% | 71.6% |
| 35 | ALKSAlkermes plc | 0.67% | 72.3% |
| 36 | BNTXBioNTech SE | 0.66% | 72.9% |
| 37 | KYMRKymera Therapeutics, Inc. | 0.64% | 73.6% |
| 38 | PCVXVaxcyte, Inc. | 0.64% | 74.2% |
| 39 | APGEApogee Therapeutics, Inc. | 0.59% | 74.8% |
| 40 | PTGXProtagonist Therapeutics, Inc. | 0.58% | 75.4% |
| 41 | RGENRepligen Corp. | 0.57% | 75.9% |
| 42 | RYTMRhythm Pharmaceuticals, Inc. | 0.57% | 76.5% |
| 43 | SYRESpyre Therapeutics, Inc. | 0.54% | 77.1% |
| 44 | BRKRBruker Corp. | 0.52% | 77.6% |
| 45 | PTCTPTC Therapeutics, Inc. | 0.51% | 78.1% |
| 46 | NUVALENT, INC. | 0.50% | 78.6% |
| 47 | TEMTempus AI, Inc. | 0.48% | 79.1% |
| 48 | TWSTTwist Bioscience Corp. | 0.48% | 79.5% |
| 49 | MIRMMirum Pharmaceuticals, Inc. | 0.45% | 80.0% |
| 50 | COGTCogent Biosciences, Inc. | 0.44% | 80.4% |
| 51 | XENEXenon Pharmaceuticals, Inc. | 0.43% | 80.9% |
| 52 | SRRKScholar Rock Holding Corp. | 0.41% | 81.3% |
| 53 | TVTXTravere Therapeutics, Inc. | 0.40% | 81.7% |
| 54 | CRSPCRISPR Therapeutics AG | 0.38% | 82.1% |
| 55 | DFTXDefinium Therapeutics, Inc. | 0.38% | 82.4% |
| 56 | ORKAOruka Therapeutics, Inc. | 0.38% | 82.8% |
| 57 | VCYTVeracyte, Inc. | 0.36% | 83.2% |
| 58 | TXG10X Genomics, Inc. | 0.34% | 83.5% |
| 59 | ACADACADIA Pharmaceuticals, Inc. | 0.33% | 83.8% |
| 60 | LEGNLegend Biotech Corp. | 0.33% | 84.2% |
| 61 | CGONCG oncology, Inc. | 0.32% | 84.5% |
| 62 | DNLIDenali Therapeutics, Inc. | 0.30% | 84.8% |
| 63 | CRNXCrinetics Pharmaceuticals, Inc. | 0.29% | 85.1% |
| 64 | ERASErasca, Inc. | 0.27% | 85.4% |
| 65 | ADPTAdaptive Biotechnologies Corp. | 0.26% | 85.6% |
| 66 | IBRXImmunityBio, Inc. | 0.26% | 85.9% |
| 67 | TNGXTango Therapeutics, Inc. | 0.26% | 86.1% |
| 68 | BEAMBeam Therapeutics, Inc. | 0.25% | 86.4% |
| 69 | EWTXEdgewise Therapeutics, Inc. | 0.25% | 86.6% |
| 70 | GPCRStructure Therapeutics, Inc. | 0.24% | 86.9% |
| 71 | IDYAIdeaya Biosciences, Inc. | 0.24% | 87.1% |
| 72 | IMVTImmunovant, Inc. | 0.24% | 87.4% |
| 73 | ARQTArcutis Biotherapeutics, Inc. | 0.23% | 87.6% |
| 74 | DYNDyne Therapeutics, Inc. | 0.23% | 87.8% |
| 75 | RAREUltragenyx Pharmaceutical, Inc. | 0.23% | 88.0% |
| 76 | GRALGRAIL, Inc. | 0.21% | 88.3% |
| 77 | NAMSNewamsterdam Pharma Co. NV | 0.21% | 88.5% |
| 78 | RLAYRelay Therapeutics, Inc. | 0.21% | 88.7% |
| 79 | QUREuniQure NV | 0.20% | 88.9% |
| 80 | RCUSArcus Biosciences, Inc. | 0.20% | 89.1% |
| 81 | TARSTarsus Pharmaceuticals, Inc. | 0.20% | 89.3% |
| 82 | VERAVera Therapeutics, Inc. | 0.20% | 89.5% |
| 83 | ELVNEnliven Therapeutics, Inc. | 0.19% | 89.7% |
| 84 | NRIXNurix Therapeutics, Inc. | 0.19% | 89.9% |
| 85 | ALMSAlumis, Inc. | 0.18% | 90.0% |
| 86 | KODKodiak Sciences, Inc. | 0.18% | 90.2% |
| 87 | VCELVericel Corp. | 0.18% | 90.4% |
| 88 | BCRXBioCryst Pharmaceuticals, Inc. | 0.17% | 90.6% |
| 89 | CAICaris Life Sciences, Inc. | 0.17% | 90.7% |
| 90 | NTLAIntellia Therapeutics, Inc. | 0.17% | 90.9% |
| 91 | AGIOAgios Pharmaceuticals, Inc. | 0.16% | 91.1% |
| 92 | IRONDisc Medicine, Inc. | 0.16% | 91.2% |
| 93 | ADMAADMA Biologics, Inc. | 0.15% | 91.4% |
| 94 | AUPHAurinia Pharmaceuticals, Inc. | 0.15% | 91.5% |
| 95 | BHVNBiohaven Ltd. | 0.15% | 91.7% |
| 96 | SMMTSummit Therapeutics, Inc. | 0.15% | 91.8% |
| 97 | ABCLAbCellera Biologics, Inc. | 0.14% | 92.0% |
| 98 | ANABAnaptysBio, Inc. | 0.14% | 92.1% |
| 99 | SNDXSyndax Pharmaceuticals, Inc. | 0.14% | 92.2% |
| 100 | SRPTSarepta Therapeutics, Inc. | 0.14% | 92.4% |
| 101 | TRVITrevi Therapeutics, Inc. | 0.14% | 92.5% |
| 102 | ZYMEZymeworks, Inc. | 0.14% | 92.7% |
| 103 | AMLXAmylyx Pharmaceuticals, Inc. | 0.13% | 92.8% |
| 104 | FTREFortrea Holdings, Inc. | 0.13% | 92.9% |
| 105 | IOVAIovance Biotherapeutics, Inc. | 0.13% | 93.1% |
| 106 | MBXMBX Biosciences, Inc. | 0.13% | 93.2% |
| 107 | MLYSMineralys Therapeutics, Inc. | 0.13% | 93.3% |
| 108 | RXRXRecursion Pharmaceuticals, Inc. | 0.13% | 93.4% |
| 109 | STOKStoke Therapeutics, Inc. | 0.13% | 93.6% |
| 110 | TSHATaysha Gene Therapies, Inc. | 0.13% | 93.7% |
| 111 | ZLABZai Lab Ltd. | 0.13% | 93.8% |
| 112 | ABSIAbsci Corp. | 0.12% | 94.0% |
| 113 | ATAIAtaiBeckley, Inc. | 0.12% | 94.1% |
| 114 | COMPASS PATHWAYS PLC | 0.12% | 94.2% |
| 115 | GRFSGrifols SA | 0.12% | 94.3% |
| 116 | NOVOCURE LTD. | 0.12% | 94.4% |
| 117 | NVAXNovavax, Inc. | 0.12% | 94.6% |
| 118 | URGNUroGen Pharma Ltd. | 0.12% | 94.7% |
| 119 | GLUEMonte Rosa Therapeutics, Inc. | 0.11% | 94.8% |
| 120 | NUVBNuvation Bio, Inc. | 0.11% | 94.9% |
| 121 | TYRATyra Biosciences, Inc. | 0.11% | 95.0% |
| 122 | VIRVir Biotechnology, Inc. | 0.11% | 95.1% |
| 123 | CDNACareDx, Inc. | 0.10% | 95.2% |
| 124 | GHRSGH Research plc | 0.10% | 95.3% |
| 125 | IMCRImmunocore Holdings plc | 0.10% | 95.4% |
| 126 | LKFTLakefront Biotherapeutics NV | 0.10% | 95.5% |
| 127 | MNKDMannKind Corp. | 0.10% | 95.6% |
| 128 | AVBPArriVent Biopharma, Inc. | 0.09% | 95.7% |
| 129 | BCAXBicara Therapeutics, Inc. | 0.09% | 95.8% |
| 130 | RAPPRapport Therapeutics, Inc. | 0.09% | 95.9% |
| 131 | SIONSionna Therapeutics, Inc. | 0.09% | 96.0% |
| 132 | XNCRXencor, Inc. | 0.09% | 96.1% |
| 133 | INBXInhibrx Biosciences, Inc. | 0.08% | 96.1% |
| 134 | MAZEMaze Therapeutics, Inc. | 0.08% | 96.2% |
| 135 | PHVSPharvaris NV | 0.08% | 96.3% |
| 136 | WVEWaVe Life Sciences Ltd. | 0.08% | 96.4% |
| 137 | CRVSCorvus Pharmaceuticals, Inc. | 0.07% | 96.5% |
| 138 | JANXJanux Therapeutics, Inc. | 0.07% | 96.5% |
| 139 | KURAKura Oncology, Inc. | 0.07% | 96.6% |
| 140 | MESOMesoblast Ltd. | 0.07% | 96.7% |
| 141 | MGTXMeiraGTx Holdings plc | 0.07% | 96.7% |
| 142 | OLMAOlema Pharmaceuticals, Inc. | 0.07% | 96.8% |
| 143 | PGENPrecigen, Inc. | 0.07% | 96.9% |
| 144 | REPLReplimune Group, Inc. | 0.07% | 96.9% |
| 145 | SEPNSepterna, Inc. | 0.07% | 97.0% |
| 146 | STEVANATO GROUP SPA | 0.07% | 97.1% |
| 147 | ABUSArbutus Biopharma Corp. | 0.06% | 97.1% |
| 148 | ANNXAnnexon, Inc. | 0.06% | 97.2% |
| 149 | ANROAlto Neuroscience, Inc. | 0.06% | 97.3% |
| 150 | BIOABioAge Labs, Inc. | 0.06% | 97.3% |
| 151 | CGEMCullinan Therapeutics, Inc. | 0.06% | 97.4% |
| 152 | GERNGeron Corp. | 0.06% | 97.4% |
| 153 | PSNLPersonalis, Inc. | 0.06% | 97.5% |
| 154 | SLDBSolid Biosciences, Inc. | 0.06% | 97.6% |
| 155 | TBPHTheravance Biopharma, Inc. | 0.06% | 97.6% |
| 156 | ZBIOZenas Biopharma, Inc. | 0.06% | 97.7% |
| 157 | ZVRAZevra Therapeutics, Inc. | 0.06% | 97.7% |
| 158 | ACRSAclaris Therapeutics, Inc. | 0.05% | 97.8% |
| 159 | CADLCandel Therapeutics, Inc. | 0.05% | 97.8% |
| 160 | CSTLCastle Biosciences, Inc. | 0.05% | 97.9% |
| 161 | CTMXCytomX Therapeutics, Inc. | 0.05% | 97.9% |
| 162 | FDMT4D Molecular Therapeutics, Inc. | 0.05% | 98.0% |
| 163 | IRWDIronwood Pharmaceuticals, Inc. | 0.05% | 98.0% |
| 164 | MRVIMaravai LifeSciences Holdings, Inc. | 0.05% | 98.1% |
| 165 | ORICORIC Pharmaceuticals, Inc. | 0.05% | 98.1% |
| 166 | PHATPhathom Pharmaceuticals, Inc. | 0.05% | 98.2% |
| 167 | RIGLRigel Pharmaceuticals, Inc. | 0.05% | 98.2% |
| 168 | SANASana Biotechnology, Inc. | 0.05% | 98.3% |
| 169 | SVRASavara, Inc. | 0.05% | 98.3% |
| 170 | ALLOAllogene Therapeutics, Inc. | 0.04% | 98.4% |
| 171 | ALTAltimmune, Inc. | 0.04% | 98.4% |
| 172 | ARVNArvinas, Inc. | 0.04% | 98.5% |
| 173 | AURAAura Biosciences, Inc. | 0.04% | 98.5% |
| 174 | CCCCC4 Therapeutics, Inc. | 0.04% | 98.5% |
| 175 | CTKBCytek Biosciences, Inc. | 0.04% | 98.6% |
| 176 | CTNMContineum Therapeutics, Inc. | 0.04% | 98.6% |
| 177 | DNAGinkgo Bioworks Holdings, Inc. | 0.04% | 98.7% |
| 178 | DSGNDesign Therapeutics, Inc. | 0.04% | 98.7% |
| 179 | MYGNMyriad Genetics, Inc. | 0.04% | 98.7% |
| 180 | OPKOPKO Health, Inc. | 0.04% | 98.8% |
| 181 | PACBPacific Biosciences of California, Inc. | 0.04% | 98.8% |
| 182 | RGNXREGENXBIO, Inc. | 0.04% | 98.9% |
| 183 | SGMTSagimet Biosciences, Inc. | 0.04% | 98.9% |
| 184 | SPRYARS Pharmaceuticals, Inc. | 0.04% | 98.9% |
| 185 | ALVOAlvotech SA | 0.03% | 99.0% |
| 186 | AUTLAutolus Therapeutics plc | 0.03% | 99.0% |
| 187 | BBOTBridgeBio Oncology Therapeutics, Inc. | 0.03% | 99.0% |
| 188 | CABACabaletta Bio, Inc. | 0.03% | 99.1% |
| 189 | EBSEmergent BioSolutions, Inc. | 0.03% | 99.1% |
| 190 | ENTAEnanta Pharmaceuticals, Inc. | 0.03% | 99.1% |
| 191 | FLGTFulgent Genetics, Inc. | 0.03% | 99.2% |
| 192 | KYTXKyverna Therapeutics, Inc. | 0.03% | 99.2% |
| 193 | NGNENeurogene, Inc. | 0.03% | 99.2% |
| 194 | PRMEPrime Medicine, Inc. | 0.03% | 99.2% |
| 195 | PRTAProthena Corp. plc | 0.03% | 99.3% |
| 196 | RCKTRocket Pharmaceuticals, Inc. | 0.03% | 99.3% |
| 197 | TECXTectonic Therapeutic, Inc. | 0.03% | 99.3% |
| 198 | VNDAVanda Pharmaceuticals, Inc. | 0.03% | 99.4% |
| 199 | AVIRAtea Pharmaceuticals, Inc. | 0.02% | 99.4% |
| 200 | AVXLAnavex Life Sciences Corp. | 0.02% | 99.4% |
| 201 | CATXPerspective Therapeutics, Inc. | 0.02% | 99.4% |
| 202 | EDITEditas Medicine, Inc. | 0.02% | 99.4% |
| 203 | FULCFulcrum Therapeutics, Inc. | 0.02% | 99.5% |
| 204 | IMRXImmuneering Corp. | 0.02% | 99.5% |
| 205 | KROSKeros Therapeutics, Inc. | 0.02% | 99.5% |
| 206 | LABStandard BioTools, Inc. | 0.02% | 99.5% |
| 207 | LCTXLineage Cell Therapeutics, Inc. | 0.02% | 99.5% |
| 208 | LXEOLexeo Therapeutics, Inc. | 0.02% | 99.6% |
| 209 | OABIOmniAb, Inc. | 0.02% | 99.6% |
| 210 | SLNSilence Therapeutics plc | 0.02% | 99.6% |
| 211 | UPBUpstream Bio, Inc. | 0.02% | 99.6% |
| 212 | AARDAardvark Therapeutics, Inc. | 0.01% | 99.6% |
| 213 | ACIUAC Immune SA | 0.01% | 99.6% |
| 214 | ADCTADC Therapeutics SA | 0.01% | 99.7% |
| 215 | ARCTArcturus Therapeutics Holdings, Inc. | 0.01% | 99.7% |
| 216 | BCYCBicycle Therapeutics plc | 0.01% | 99.7% |
| 217 | BDTXBlack Diamond Therapeutics, Inc. | 0.01% | 99.7% |
| 218 | CDXSCodexis, Inc. | 0.01% | 99.7% |
| 219 | CLLSCellectis SA | 0.01% | 99.7% |
| 220 | CRBUCaribou Biosciences, Inc. | 0.01% | 99.7% |
| 221 | FHTXFoghorn Therapeutics, Inc. | 0.01% | 99.7% |
| 222 | HUMAHumacyte, Inc. | 0.01% | 99.7% |
| 223 | LENZLENZ Therapeutics, Inc. | 0.01% | 99.7% |
| 224 | LRMRLarimar Therapeutics, Inc. | 0.01% | 99.8% |
| 225 | LYELLyell Immunopharma, Inc. | 0.01% | 99.8% |
| 226 | NMRANeumora Therapeutics, Inc. | 0.01% | 99.8% |
| 227 | NOVABRIDGE BIOSCIENCES | 0.01% | 99.8% |
| 228 | PEPGPepGen, Inc. | 0.01% | 99.8% |
| 229 | PYXSPyxis Oncology, Inc. | 0.01% | 99.8% |
| 230 | QSIQuantum-Si, Inc. | 0.01% | 99.8% |
| 231 | QTRXQuanterix Corp. | 0.01% | 99.8% |
| 232 | TNYATenaya Therapeutics, Inc. | 0.01% | 99.8% |
| 233 | TRDAEntrada Therapeutics, Inc. | 0.01% | 99.8% |
| 234 | VYGRVoyager Therapeutics, Inc. | 0.01% | 99.9% |
Funds that hold the most of the same stocks
The share of IBB that is also in each fund, from the positions both report. Open a pair for the full list.
| Fund | Overlap | Shared |
|---|---|---|
| XBIState Street(R) SPDR(R) S&P(R) Biotech ETF | 41.1% | 121 |
| LABUDirexion Daily S&P Biotech Bull 3X Shares | 39.0% | 118 |
| VHTVANGUARD HEALTH CARE INDEX FUND | 17.6% | 149 |
| IYHiShares U.S. Healthcare ETF | 15.9% | 29 |
| IWOiShares Russell 2000 Growth ETF | 15.3% | 118 |
| VBKVANGUARD SMALL-CAP GROWTH INDEX FUND | 12.0% | 52 |
| XLVState Street(R) Health Care Select Sector SPDR(R) ETF | 11.1% | 9 |
| IWMiShares Russell 2000 ETF | 10.4% | 163 |
Questions people ask
What are the top holdings of IBB?
Its filing lists 234 stock positions. The largest are VRTX 8.1%, AMGN 7.8%, GILD 6.8%, and the ten largest together are 44.8% of the fund. The full list with weights is on this page.
How often do these holdings change?
Funds report their positions to the SEC at each quarter end, and the SEC publishes the filing about 60 days later. Ploutos reads the latest one every week, so the page changes four times a year, and shows the date of the filing it reads.
Why does the coverage not reach 100%?
The list is the stock positions the fund reports. Cash, futures, bonds and other assets the filing carries are not listed, and what the stocks add up to is the coverage shown. A stock fund lands near 100; a fund that holds futures or a cash sleeve lands lower. Weights are of the whole fund.
Compare IBB with another fund·All fund pairs
Descriptive data from public SEC filings. Nothing on this page is a recommendation to buy, sell or hold any fund or stock, and holdings change between filings.